(Mesenchymal) Stem Cell-Based Therapy in Cisplatin-Induced Acute Kidney Injury Animal Model: Risk of Immunogenicity and Tumorigenicity by Ž. Večerić-Haler, A. Cerar, M. Perše

“…Since the risk of tumorigenicity of particular therapy as well as the immune response to solid or cell grafts is a major issue in clinical trials, the aim of the present paper is to critically summarize the results of MSC transplantation on animal models of AKI, particularly cisplatin-induced animal models, and to expose results and main concerns about immunogenicity and tumorigenicity of transplanted MSCs, two important issues that need to be addressed in future studies.…”
Get full text

Ribitol and ribose treatments differentially affect metabolism of muscle tissue in FKRP mutant mice by Marcela P. Cataldi, Qi L. Lu

“…Supplement of ribitol and ribose have been reported to increase the levels of CDP-ribitol in both cells and in muscles in vivo. Clinical trials with both ribitol and ribose have been reported for treating LGMD2I caused by mutations in the FKRP gene. …”
Get full text

Probiotics and Paraprobiotics—New Proposal for Functional Food by Barbara Sionek, Magdalena Gantner

“…The safety profile favors them for usage in vulnerable people; however, their effectiveness should be proven in clinical trials. Paraprobiotics do not carry the risk of antibiotic resistance, transfer, or acquisition. …”
Get full text

Pre-trained convolutional neural network with transfer learning by artificial illustrated images classify power Doppler ultrasound images of rheumatoid arthritis joints by Jun Fukae, Yoshiharu Amasaki, Yuichiro Fujieda, Yuki Sone, Ken Katagishi, Tatsunori Horie, Tamotsu Kamishima, Tatsuya Atsumi

“…The study was registered in UMIN Clinical Trials Registry (UMIN000054321). Results A total of 156 clinical joint ultrasound images from 74 patients with RA were included. …”
Get full text

Transformative advancements in immune checkpoint inhibitor therapy for Oropharyngeal Squamous Cell Carcinoma (OPSCC) by Iadalin Ryntathiang, Mukesh Kumar Dharmalingam Jothinathan

“…Furthermore, current clinical trials are exploring innovative combinations of ICIs and treatment sequences in order to enhance patient outcomes. …”
Get full text

Pharmacotherapy of Peptic Ulcer Disease by F Molina, MM Vohra, CN Williams

“…Combination therapy has not yet proved to be better than single drug therapy; however, the number of studies is still small, and more clinical trials are necessary. Resistant ulcers have demonstrated that acid is one of several etiological factors and that more research is needed to elucidate the reason(s) for refractoriness. …”
Get full text

The Natural History of Pancreatic Cancer in Manitoba: A Population Based Study by Jack Martin, Brian H Weinerman

“…The poor prognosis of all individuals confirms the rationale of trying to develop better treatments for all stages of disease, and stage and pathological differentiation should be taken into account when designing clinical trials.…”
Get full text

Translating Research into Clinical Scale Manufacturing of Mesenchymal Stromal Cells by Karen Bieback, Sven Kinzebach, Marianna Karagianni

“…The challenge relates to managing the expected therapeutic benefits with the potential risks and to balance the fast move to clinical trials with time-consuming cautious risk assessment. …”
Get full text

The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment by Ze-Tao Zhan, Lu Liu, Ming-Zhen Cheng, Yi Gao, Wei-Jie Zhou

“…Based on this study, further clinical trials are expected.…”
Get full text

The Relationship Between the Modulation of Intestinal Microbiota and the Response to Immunotherapy in Patients with Cancer by Laura Radoš, Marin Golčić, Ivana Mikolašević

“…Fecal transplantation is a safe and realistic adjuvant option for the treatment of cancer patients with immunotherapy, but more clinical trials are necessary. Modulating the microbiota composition indeed changes the effectiveness of immunotherapy, but in the future, more human studies should be organized to precisely determine the types and procedures of microbiota modulation.…”
Get full text

An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic Neuropathy by Zunaira Qureshi, Murtaza Najabat Ali, Minahil Khalid

“…Treating painful symptoms in diabetic patient can be frustrating not only for the patients but also for health care workers, so additional clinical trials for novel and conventional treatments are required to devise more effective treatment for PDN with minimal side effects. …”
Get full text

Levosimendan for sepsis-induced myocardial dysfunction: friend or foe? by Xinxin Du, Xinxin Du, Fang Xiong, Yafei Hou, Xiangyou Yu, Pengfei Pan

“…We also analyzed the potential and limitations of levosimendan for the treatment of SIMD to provide ideas for future clinical trials and the clinical application of levosimendan in SIMD.…”
Get full text

Fine-tuning SLE treatment: the potential of selective TYK2 inhibition by Yoshiya Tanaka, Shingo Nakayamada, Yurie Satoh-Kanda

“…Although several JAK/TYK2 inhibitors are currently undergoing clinical trials, more selective drugs that can target cytokine signals according to the specific pathology of the disease are required. …”
Get full text

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes by María Isabel del Olmo-Garcia, Juan Francisco Merino-Torres

“…On the other hand, recent clinical trials aimed at studying cardiovascular episodes have been conducted with GLP-1 RAs. …”
Get full text

Regulatory T Cells in Autoimmune and Viral Chronic Hepatitis by Pascal Lapierre, Alain Lamarre

“…With the recent advent of monoclonal antibodies able to target regulatory T cells (daclizumab) and improve immune responses and several ongoing clinical trials analysing the impact of regulatory T cell infusion on autoimmune liver disease or liver transplant tolerance, modulation of immunological tolerance through CD4+ regulatory T cells could be a key element of future immunotherapies for several liver diseases allowing restoring the balance between proper immune responses and tolerance.…”
Get full text

The Microbiome-Gut-Brain Axis, Nutrition and Parkinson’s Disease by Jevgenija Guk, Rūta Kaladytė Lokominienė, Dalius Jatužis

“…Although epidemiological and experimental studies in animal models have shown their neuroprotective properties, their effectiveness was not confirmed in clinical trials. However, daily food intake comprises many nutrients that can interact and produce either a synergistic or antagonistic effect on the human body. …”
Get full text

The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature by Ioanna Tsiouprou, Athanasios Zaharias, Dionisios Spyratos

“…During the past few years, several clinical trials have evaluated the effect of addition of immunotherapy to conventional chemotherapy in patients with extensive SCLC. …”
Get full text

Targeting Apoptosis Pathways in Cancer with Alantolactone and Isoalantolactone by Azhar Rasul, Muhammad Khan, Muhammad Ali, Jiang Li, Xiaomeng Li

“…This review suggests that alantolactone and isoalantolactone are potential promising anticancer candidates, but additional studies and clinical trials are required to determine their specific intracellular sites of actions and derivative targets in order to fully understand the mechanisms of therapeutic effects to further validate in cancer chemotherapy.…”
Get full text

Case report: Exploring efficacy of tofacitinib in modulating interferon response in five case of anti-MDA5+ dermatomyositis with interstitial lung disease by Jie Zhao, Yan Bao, Ying Gao, Keliang Xie

“…Urgent and well-designed clinical trials are imperative to unravel the intricate interplay between RP-ILD and the IFN signature in MDA5-DM, and to evaluate novel therapeutic targets that promise long-term efficacy and safety.…”
Get full text

A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines by Jose Miguel Rubio-Perez, Juana Maria Morillas-Ruiz

“…It has been observed in epidemiological studies that treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) decreases the risk for developing AD. Unfortunately, clinical trials of NSAIDs in AD patients have not been very fruitful. …”
Get full text